Allergy Therapeutics plc (AGYTF)

Market Cap	408.35M
Revenue (ttm)	69.68M
Net Income (ttm)	-44.63M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,001
Average Volume	16,019
Open	0.0820
Previous Close	0.1000
Day's Range	0.0820 - 0.0820
52-Week Range	0.0200 - 0.1000
Beta	1.23
RSI	44.49
Earnings Date	Jun 27, 2025

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to ad...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 612
• Stock Exchange: OTCMKTS
• Ticker Symbol: AGYTF

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.

Financial numbers in GBP